Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 500K | 0 | 0 | 0 | 0 |
| Gross Profit | 500K | 0 | 0 | 0 | 0 |
| Operating Income | -5M | -9M | -11M | -8M | -7M |
| EBITDA | -5M | -9M | -11M | -7M | -7M |
| Net Income | -7M | -11M | -13M | -8K | -7K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.05
+0.00% today
1Y Change
+25.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 243 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zenith Capital Corp. (ZHCLF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.05 and up 25.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +31.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +31.2%, free cash flow +100.0% with operating margin -886.4% and ROIC 0.0%. Valuation already assumes a fairly strong business story at price/sales 17.6. Stock Foundry combines ZHCLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZHCLF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZHCLF Max Drawdown
-99.83%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZHCLF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$6.9K
+11.3% YoY
Free Cash Flow
-$7.9K
-835.9% YoY
Revenue Growth
+0.0%
EPS Growth
+31.2%
Gross Margin
100.0%
Net Margin
-1406.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 500K | 0 | 0 | 0 | 0 |
| Gross Profit | 500K | 0 | 0 | 0 | 0 |
| Operating Income | -5M | -9M | -11M | -8M | -7M |
| EBITDA | -5M | -9M | -11M | -7M | -7M |
| Net Income | -7M | -11M | -13M | -8K | -7K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 161 | 29 | 8 | 7 |
| Total Assets | 0 | 7K | 3K | 3K | 3K |
| Total Liabilities | 0 | 28K | 18K | 5K | 6K |
| Shareholder Equity | 0 | -20K | -15K | -14K | -10K |
| Total Debt | 0 | 10K | 4K | 3K | 3K |
| Net Debt | 0 | 10K | 4K | 3K | 3K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
8K
-835.9% YoY
Capital Expenditures
0
Free Cash Flow
8K
-835.9% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-886.4%
Net Margin
-1406.2%
ROE
0.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.